CL2014002556A1 - Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras. - Google Patents

Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.

Info

Publication number: CL2014002556A1
Authority: CL; Chile
Prior art keywords: indanyloxidihydrobenzofuranylacetic; obesity; diabetes; diseases; acids
Prior art date: 2012-03-26

Application number

CL2014002556A

Other languages

English (en)

Inventor

Holger Wagner

Frank Himmelsbach

Elke Langkopf

Matthias Eckhardt

Sara Frattini

Dieter Hamprecht

Stefan Petersw

Iain Lingard

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-26

Filing date

2014-09-25

Publication date

2015-02-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002556(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-25 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-02-13 Publication of CL2014002556A1 publication Critical patent/CL2014002556A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CL2014002556A 2012-03-26 2014-09-25 Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras. CL2014002556A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP12161240		2012-03-26

Publications (1)

Publication Number	Publication Date
CL2014002556A1 true CL2014002556A1 (es)	2015-02-13

Family

ID=48013980

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002556A CL2014002556A1 (es)	2012-03-26	2014-09-25	Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.

Country Status (23)

Country	Link
US (1)	US8642585B2 (es)
EP (2)	EP2831053B1 (es)
JP (2)	JP6131492B2 (es)
KR (1)	KR20140139088A (es)
CN (1)	CN104321319A (es)
AP (1)	AP2014007903A0 (es)
AR (1)	AR090493A1 (es)
AU (1)	AU2013241926A1 (es)
CA (1)	CA2868474A1 (es)
CL (1)	CL2014002556A1 (es)
CO (1)	CO7091175A2 (es)
EA (1)	EA201401053A1 (es)
EC (1)	ECSP14023238A (es)
HK (1)	HK1201260A1 (es)
MA (1)	MA20150065A1 (es)
MX (1)	MX2014011465A (es)
PE (1)	PE20142019A1 (es)
PH (1)	PH12014502141A1 (es)
SG (1)	SG11201405713UA (es)
TN (1)	TN2014000398A1 (es)
TW (1)	TW201400466A (es)
UY (1)	UY34704A (es)
WO (2)	WO2013144098A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2546154T3 (es) *	2010-12-01	2015-09-21	Boehringer Ingelheim International Gmbh	Ácidos indaniloxidihidrobenzofuranilacéticos, útiles para el tratamiento del síndrome metabólico
US8642585B2 (en) *	2012-03-26	2014-02-04	Boehringer Ingelheim International Gmbh	Indanyloxydihydrobenzofuranylacetic acids
CN105473595A (zh) *	2013-08-23	2016-04-06	福建海西新药创制有限公司	治疗糖尿病的羧酸化合物
WO2015097713A1 (en)	2013-11-14	2015-07-02	Cadila Healthcare Limited	Novel heterocyclic compounds
WO2015084692A1 (en)	2013-12-04	2015-06-11	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
EP3102198B1 (en)	2014-02-06	2020-08-26	Merck Sharp & Dohme Corp.	Antidiabetic compounds
US10100042B2 (en)	2014-08-08	2018-10-16	Merck Sharp & Dohme Corp.	[5,6]—fused bicyclic antidiabetic compounds
JP2018526405A (ja) *	2015-09-09	2018-09-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用
CN110312706B (zh)	2016-11-28	2023-08-18	勃林格殷格翰国际有限公司	茚满基氨基吡啶基环丙烷甲酸、其药物组合物及用途
CN110248929B (zh)	2017-01-26	2023-05-12	勃林格殷格翰国际有限公司	苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
WO2018138027A1 (en)	2017-01-26	2018-08-02	Boehringer Ingelheim International Gmbh	Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof
JP6968181B2 (ja)	2017-01-26	2021-11-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7050792B2 (ja)	2017-01-26	2022-04-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
EP3573953A1 (en)	2017-01-26	2019-12-04	Boehringer Ingelheim International GmbH	Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018146008A1 (en)	2017-02-08	2018-08-16	Boehringer Ingelheim International Gmbh	Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
WO2018181847A1 (ja) *	2017-03-31	2018-10-04	武田薬品工業株式会社	芳香環化合物
WO2019110464A1 (en) *	2017-12-04	2019-06-13	Basf Se	Method for preparing ethers of cycloaliphatic or araliphatic diols
US11312709B2 (en)	2018-02-05	2022-04-26	Glaxosmithkline Intellectual Property Development Limited	Ghrelin O-acyltransferase inhibitors
PL3752501T3 (pl)	2018-02-13	2023-08-21	Gilead Sciences, Inc.	Inhibitory pd-1/pd-l1
CA3093851A1 (en)	2018-03-29	2019-10-03	Arbutus Biopharma Corporation	Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
TWI712412B (zh)	2018-04-19	2020-12-11	美商基利科學股份有限公司	Pd‐1/pd‐l1抑制劑
US10774071B2 (en)	2018-07-13	2020-09-15	Gilead Sciences, Inc.	PD-1/PD-L1 inhibitors
JP2021536445A (ja) *	2018-08-29	2021-12-27	ケモセントリックス，インコーポレイティド	小型分子ｐｄ−ｌ１インヒビターによる癌治療法
TW202028183A (zh) *	2018-10-10	2020-08-01	大陸商江蘇豪森藥業集團有限公司	含氮雜芳類衍生物調節劑、其製備方法和應用
CN112955435B (zh)	2018-10-24	2024-09-06	吉利德科学公司	Pd-1/pd-l1抑制剂
AU2020363377A1 (en)	2019-10-07	2022-04-21	Kallyope, Inc.	GPR119 agonists
EP4110788A4 (en)	2020-02-28	2024-08-28	Kallyope, Inc.	Gpr40 agonists
JP2023526625A (ja)	2020-05-19	2023-06-22	キャリーオペ，インク．	Ａｍｐｋアクチベーター
JP2023531726A (ja)	2020-06-26	2023-07-25	キャリーオペ，インク．	Ａｍｐｋアクチベーター

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003277576A1 (en)	2002-11-08	2004-06-07	Takeda Pharmaceutical Company Limited	Receptor function controlling agent
CN1735408A (zh) *	2002-11-08	2006-02-15	武田药品工业株式会社	受体机能调节剂
JP4594611B2 (ja) *	2002-11-08	2010-12-08	武田薬品工業株式会社	受容体機能調節剤
US7820837B2 (en)	2003-05-30	2010-10-26	Takeda Pharmaceutical Company Limited	Condensed ring compound
JP4805552B2 (ja) *	2003-05-30	2011-11-02	武田薬品工業株式会社	縮合環化合物
KR20080103584A (ko)	2006-03-30	2008-11-27	아사히 가세이 파마 가부시키가이샤	치환 이환식 환상 유도체 및 그 용도
NZ574038A (en)	2006-06-27	2011-12-22	Takeda Pharmaceutical	Fused cyclic compounds as GPR40 receptor function modulators, for treating diabetes
RU2011102560A (ru)	2008-06-25	2012-07-27	Дайити Санкио Компани, Лимитед (Jp)	Соединение карбоновой кислоты
ES2450567T3 (es)	2008-10-15	2014-03-25	Amgen, Inc	Moduladores de GPR40 espirocíclicos
WO2010143733A1 (en)	2009-06-09	2010-12-16	Takeda Pharmaceutical Company Limited	Novel fused cyclic compound and use thereof
TW201643169A (zh) *	2010-07-09	2016-12-16	艾伯維股份有限公司	作為s1p調節劑的螺-哌啶衍生物
ES2546154T3 (es)	2010-12-01	2015-09-21	Boehringer Ingelheim International Gmbh	Ácidos indaniloxidihidrobenzofuranilacéticos, útiles para el tratamiento del síndrome metabólico
US8642585B2 (en) *	2012-03-26	2014-02-04	Boehringer Ingelheim International Gmbh	Indanyloxydihydrobenzofuranylacetic acids

2013
- 2013-03-14 US US13/803,237 patent/US8642585B2/en active Active
- 2013-03-22 UY UY0001034704A patent/UY34704A/es unknown
- 2013-03-25 PE PE2014001462A patent/PE20142019A1/es not_active Application Discontinuation
- 2013-03-25 CA CA2868474A patent/CA2868474A1/en not_active Abandoned
- 2013-03-25 JP JP2015502285A patent/JP6131492B2/ja active Active
- 2013-03-25 HK HK15101722.6A patent/HK1201260A1/xx unknown
- 2013-03-25 CN CN201380026597.0A patent/CN104321319A/zh active Pending
- 2013-03-25 EP EP13724175.8A patent/EP2831053B1/en active Active
- 2013-03-25 WO PCT/EP2013/056313 patent/WO2013144098A1/en active Application Filing
- 2013-03-25 TW TW102110560A patent/TW201400466A/zh unknown
- 2013-03-25 MA MA37429A patent/MA20150065A1/fr unknown
- 2013-03-25 AP AP2014007903A patent/AP2014007903A0/xx unknown
- 2013-03-25 JP JP2015502284A patent/JP6040486B2/ja active Active
- 2013-03-25 EP EP13712760.1A patent/EP2831064B1/en active Active
- 2013-03-25 WO PCT/EP2013/056312 patent/WO2013144097A1/en active Application Filing
- 2013-03-25 EA EA201401053A patent/EA201401053A1/ru unknown
- 2013-03-25 KR KR20147030011A patent/KR20140139088A/ko not_active Withdrawn
- 2013-03-25 MX MX2014011465A patent/MX2014011465A/es unknown
- 2013-03-25 SG SG11201405713UA patent/SG11201405713UA/en unknown
- 2013-03-25 AR ARP130100969A patent/AR090493A1/es unknown
- 2013-03-25 AU AU2013241926A patent/AU2013241926A1/en not_active Abandoned
2014
- 2014-09-22 TN TNP2014000398A patent/TN2014000398A1/fr unknown
- 2014-09-25 PH PH12014502141A patent/PH12014502141A1/en unknown
- 2014-09-25 CL CL2014002556A patent/CL2014002556A1/es unknown
- 2014-09-26 CO CO14213969A patent/CO7091175A2/es unknown
- 2014-10-17 EC ECIEPI201423238A patent/ECSP14023238A/es unknown

Also Published As

Publication number	Publication date
CN104321319A (zh)	2015-01-28
MX2014011465A (es)	2015-01-12
MA20150065A1 (fr)	2015-02-27
CA2868474A1 (en)	2013-10-03
HK1201260A1 (en)	2015-08-28
JP2015511612A (ja)	2015-04-20
EP2831053A1 (en)	2015-02-04
UY34704A (es)	2013-09-30
AP2014007903A0 (en)	2014-08-31
JP2015511613A (ja)	2015-04-20
PH12014502141A1 (en)	2014-12-01
US20130252937A1 (en)	2013-09-26
ECSP14023238A (es)	2015-09-30
EP2831053B1 (en)	2016-06-22
AU2013241926A1 (en)	2014-09-18
JP6040486B2 (ja)	2016-12-07
EA201401053A1 (ru)	2015-04-30
CO7091175A2 (es)	2014-10-21
SG11201405713UA (en)	2014-10-30
WO2013144097A1 (en)	2013-10-03
EP2831064A1 (en)	2015-02-04
JP6131492B2 (ja)	2017-05-24
TN2014000398A1 (en)	2015-12-21
TW201400466A (zh)	2014-01-01
KR20140139088A (ko)	2014-12-04
EP2831064B1 (en)	2016-02-17
WO2013144098A1 (en)	2013-10-03
US8642585B2 (en)	2014-02-04
PE20142019A1 (es)	2014-12-18
AR090493A1 (es)	2014-11-19

Publication	Publication Date	Title
CL2014002556A1 (es)	2015-02-13	Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
AR092925A1 (es)	2015-05-06	Derivados de exendina-4 como agonistas duales de glp1 / glucagon
CL2013002053A1 (es)	2013-11-29	Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
AR099912A1 (es)	2016-08-31	Derivados de exendina-4 como agonistas dobles de glp1 / gip o triples de glp1 / gip / glucagon
CL2014003421A1 (es)	2015-05-22	Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2014000458A1 (es)	2014-09-05	Compuestos derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina; composicion y combinacion farmaceutica; y uso en el tratamiento o en la prevencion del alzheimer, diabetes tipo 2, obesidad, entre otras enfermedades.
CL2009000173A1 (es)	2010-02-12	Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
AR098738A1 (es)	2016-06-08	Análogos del péptido exendina-4 no acilados
UY34859A (es)	2014-01-31	Análogos peptídicos de la exendina 4.
LT2916860T (lt)	2020-07-10	Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
UY32094A (es)	2010-04-30	Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden dichos compuestos y su uso.
CL2015001699A1 (es)	2015-10-30	Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
CL2008002111A1 (es)	2008-10-24	Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
CL2014001994A1 (es)	2014-11-03	Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
CL2013002414A1 (es)	2014-01-24	Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
HUE061596T2 (hu)	2023-07-28	Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
CL2013001964A1 (es)	2013-11-29	Compuestos derivados de heterociclos, como inhibidores de bace 1 o 2; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento o prevencion de la enfermedad de alzheimer o deterioro cognitivo leve, resistencia a la insulina, diabetes tipo 2, entre otras.
GT200900230A (es)	2011-11-29	4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2014002757A1 (es)	2015-01-23	Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
EP2718317A4 (en)	2015-04-08	GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
CL2015001537A1 (es)	2015-10-23	Compuestos derivados de piridin-2-amidas agonistas cb2; proceso de sintesis; composicion farmaceutica; uso en el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras.
MX2014014946A (es)	2015-04-08	Uso de peptidos glp-1 de accion prolongada.
CL2015001318A1 (es)	2015-10-02	Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras.
CL2015001724A1 (es)	2015-10-16	Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros.